Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$1.11 USD
-0.05 (-4.31%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $1.12 +0.01 (0.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Protalix BioTherapeutics, Inc. [PLX]
Reports for Purchase
Showing records 21 - 40 ( 77 total )
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary BRIDGE Study Data Indicate Potential Superiority of PRX-102 vs. Replagal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q 2018 Financial Results Reported; Top- and Bottom-Line Miss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Partnered in U.S. With Chiesi; Reiterate Buy and Reducing Target to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional OPRX-106 Phase 2a Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q 2018 Results Reported; Revenue Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Complete Top-Line Data Reported From Phase 2 OPRX-106 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q and FY2017 Results Reported; Fabry Program Should Complete Enrollment in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OPRX-106 Trial Patient Dosing Complete; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WORLDSymposium Data Strengthen Case for PRX-102 in Fabry Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Receives FDA Fast Track Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Data Reported in Ulcerative Colitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Incremental Phase 1/2 Data for PRX-102; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q17 Financial Results Reported; Chiesi Partnership Reduces Risk; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Financial Results Reported; Clinical Progress Continues; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Financial Results Reported; Clinical Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Cystic Fibrosis Data Presented; Multi-Product Facility Authorized; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Cystic Fibrosis Data Presented; Multi-Product Facility Authorized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Financials Reported; Brazilian Elelyso Demand Coming Online; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Financials Reported; Brazilian Elelyso Demand Coming Online; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AIR DNase Demonstrates Potential; Raising Price Target
Provider: Rodman & Renshaw, Co.